{
  "study_metadata": {
    "study_id": null,
    "design": "RCT"
  },
  "exposure": {
    "label": "resveratrol",
    "comparator": "placebo"
  },
  "outcomes": [
    {
      "name": "HbA1c",
      "timepoint_weeks": 26,
      "arm_name": "intervention",
      "n": 23,
      "baseline_mean": 5.83,
      "baseline_sd": 0.2,
      "followup_mean": 5.7,
      "followup_sd": 0.2,
      "units": "%"
    },
    {
      "name": "HbA1c",
      "timepoint_weeks": 26,
      "arm_name": "control",
      "n": 23,
      "baseline_mean": 5.85,
      "baseline_sd": 0.3,
      "followup_mean": 5.88,
      "followup_sd": 0.3,
      "units": "%"
    }
  ],
  "comment_detailed": "I searched the Methods and Results sections for glycemic outcomes. The study reports HbA1c values pre‑ and post‑26 weeks for both groups, with means and SDs. No other glucose metrics (HOMA‑IR, FPG) were reported, so those fields remain null. The study ID was not provided. The design is a double‑blind, placebo‑controlled RCT. Evidence snippets are drawn from Table 5 and the text describing HbA1c changes.",
  "comment": "HbA1c reduced in resveratrol group; no other glycemic data.",
  "evidence": [
    "\"HbA1c, %a5.83/H110060.2 5.70 /H110060.2\"",
    "\"Subjects of the resveratrol group showed a significant reduction in HbA1c\"",
    "\"Table 5. Fasting serum parameters, anthropometric measures, vascular parameters, physical activity, and mood of subjects before and after the intervention/control period\""
  ],
  "missing_fields": [
    "study_metadata.study_id"
  ],
  "confidence": 0.9
}